The fasting lipid profile does not necessarily illustrate the dynamic features of lipid metabolism over a 24 hour period as human subjects are in the postprandial (PP) state for most of the day. PP triglyceride (TG) measurement in plasma has been reported to have advantages compared to fasting TG in terms of practicality and the ability to predict cardiovascular risk.
Residual risk beyond LDL: A new apoB-centred framework for atherosclerosis
Professor Jan Borén, Institute of Medicine, University of Gothenburg, Sweden, welcomes the timely reframing of apoB biology presented in Professor Chris Packard’s video presentation ‘ApoB and atherosclerosis 2026: Answers and Questions‘, highlighting its importance in moving the field beyond the LDL-centric model to a more integrated view which includes the atherogenic potential and clinical significance of triglyceride-rich lipoproteins and Lp(a).
Hypertriglyceridaemia: Where next for cardiovascular outcomes trials?
Highly effective agents are now available, such as olezarsen and plozasiran, that reduce triglyceride (TG) levels by 60-70% in patients with severe hypertriglyceridaemia (sHTG >5.6-10 mmol/L or 500-880 mg/dL), and there is growing evidence of comparable reductions in patients with moderate hypertriglyceridaemia (mHTG, 1.7-5.6 mmol/L or 150 -499 mg/dL). However, evidence that TG reductions translate into positive CV outcomes is limited.
Novel therapies in hypertriglyceridaemia: Trial results in 2025 and what’s to come in 2026
Novel therapies for hypertriglyceridaemia (HTG) reached some major milestones in 2025 including impressive clinical trial results across the three targets for these emerging treatments – ANGPTL3, ANGPTL4 and apoC3 – and the first regulatory approvals for apoC3 inhibitors in patients with familial chylomicronaemia syndrome (FCS). Just as exciting are expectations for 2026, as studies of apoC3-targeting agents continue down the HTG pyramid of severity and ANGPTL3 and ANGPTL4-targeting agents advance from early into later phase clinical trials.
Metabolic fatty liver disease: How are triglycerides involved?
Hypertriglyceridaemia (HTG) is an important risk factor for metabolic fatty liver disease – an umbrella term for multiple common chronic liver diseases for which triglyceride-lowering agents are starting to show encouraging benefits. Professor Robert Rosenson (Icahn School of Medicine at Mount Sinai, New York, USA) examines the evidence linking triglycerides to fatty liver disease and current and potential approaches to treatment.
ANGPTL4: An important regulator of cholesterol and triglyceride metabolism
As the first agents targeting ANGPTL4 progress through clinical trials investigating their potential to lower triglyceride levels, Professor Sander Kersten (Cornell University, New York, USA) considers the role of ANGPTL4 in lipid metabolism, its mechanism of action, and latest data supporting the growing interest in ANGPTL4 inhibition as an opportunity for reducing cardiovascular risk.
